Skip to content

Improving the outcome of chronic subdural hematoma by embolization of the middle meningeal artery (ELIMINATE).

Improving the outcome of chronic subdural hematoma by embolization of the middle meningeal artery (ELIMINATE). - Embolization in chronic subdural hematoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55323
Enrollment
180
Registered
2020-03-10
Start date
2020-12-10
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bleeding in the subdural space stroke bleeding in the subdural space stroke

Interventions

Peri-operative embolization until 72 hours after surgery.

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Has a head-CT or MRI confirmed diagnosis of cSDH - Primary surgical treatment based on clinical symptoms (progressive neurological deficits)

Exclusion criteria

Exclusion criteria: - Significant contraindication to angiography (eg. allergy for contrast, inability to lay still); - Structural causes for subdural haemorrhage, e.g. arachnoid cysts, cortical vascular malformations and a history of cranial surgery

Design outcomes

Primary

MeasureTime frame
The difference in reoperation rate between the control group and the intervention group.

Secondary

MeasureTime frame
1. Volume/size of cSDH at 12 and 24 weeks on follow-up CT scan of the head. 2. Number of procedure related complications during hospital admission and 24 week follow-up. 3. Neurological impairment at 12and 24 weeks, measured with the modified National Institutes of Health Stroke Scale (mNIHSS ) score and Markwalder score. 4. Functional outcome at 24 weeks, measured with the modified Rankin Scale (mRS) score. 5. Cognitive functioning at 12 weeks and 24 measured with the Montreal Cognitive Assessment (MOCA) test and m-TICS. 6. Mortality at 24 weeks. 7. Performance in activities of daily living at 24 weeks, measured with the Barthel Index. 8. Quality of life at 24 weeks, measured with the a. Short Form Health Survey (SF-36) questionnaire; b. five dimensional EuroQol (EQ-5D-3L) questionnaire. 9 Care and health-related costs during the 24 week study period, measured with the a. Medical Consumption Questionnaire (iMCQ); b. Productivity Cost Questionnaire (iPCQ).

Countries

Netherlands

Contacts

Public ContactMF Serlé

Amsterdam UMC

m.f.serle@amsterdamumc.nl0205669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 21, 2026